Skip to main content
SpringerLink
Log in

Managing and Predicting Low Response to Standard In Vitro Fertilization Therapy

A Review of the Options

  • Review Article
  • Published:
Treatments in Endocrinology

Abstract

Low responders remain a difficult group of patients to manage in an in vitro fertilization (IVF) program. Such patients have low peak estradiol concentrations (<500 ng/L) and few dominant follicles on the day of human chorionic gonadotropin administration (<5 to <2), and therefore have few retrieved mature oocytes (≤4 to ≤6) with resultant lower pregnancy rates when stimulated with standard IVF therapy (daily gonadotropin dose 150–300IU [2–4 ampoules]). It is difficult to compare the various strategies that have been utilized to manage low responders because the definition of a low responder varies widely. Also, very few large prospective randomized trials have compared different protocols. Two stimulation protocols involving varying doses of leuprorelin and high doses of gonadotropins appear to be the most promising. The early gonadotropin-releasing hormone (GnRH) agonist cessation protocol involves routine pituitary desensitization with luteal phase start of leuprorelin 0.5mg for 10–14 days. With the onset of gonadotropin treatment, there is cessation of leuprorelin. The ‘microdose flare’ protocol utilizes oral contraceptive priming followed by diluted doses of leuprorelin 50μg given twice daily. Two days later, stimulation is started by adding high doses of gonadotropins. The microdoses of leuprorelin and the high doses of gonadotropins are then continued until the day of chorionic gonadotropin administration. Patients who do not respond to these protocols or those with severely diminished ovarian reserve are candidates for donor oocytes. The role of GnRH antagonists and the in vitro maturation of oocytes are potentially exciting strategies that are still being investigated.

Ultrasound measurements of ovarian volume, baseline antral follicle counts, and Doppler measurement of ovarian stromal blood flow now make it possible to predict low response to IVF therapy. Low response can be expected if the smaller ovary has a volume <3 cm3, or the mean ovarian diameter in the two longest planes is <20mm. Antral follicle counts of ≤3 in each ovary are also associated with low response. Data on ovarian stromal blood flow are still unclear, but an ovarian peak systolic velocity of <10 cm/sec is associated with low response. If low response is anticipated based on baseline ultrasound scan, a switch to one of the two effective stimulation protocols should be initiated. This would reduce cancellation rates and improve pregnancy rates in the first cycle of IVF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Keay SD, Liversedge NH, Mathur RS, et al. Assisted conception following poor ovarian response to gonadotrophin stimulation. Br J Obstet Gynaecol 1997 May; 104(5): 521–7

    Article  PubMed  CAS  Google Scholar 

  2. Karande V, Gleicher N. A rational approach to the management of low responders in in-vitro fertilization. Hum Reprod 1999 Jul; 14(7): 1744–8

    Article  PubMed  CAS  Google Scholar 

  3. Lee DW, Grasso P, Dattatreyamurty B, et al. Purification of a high molecular weight follicle-stimulating hormone receptor-binding inhibitor from human follicular fluid. J Clin Endocrinol Metab 1993 Jul; 77(1): 163–8

    Article  PubMed  CAS  Google Scholar 

  4. Sanzo MA, Reichert Jr LE. Gonadotropin receptor binding regulators in serum: characterization and separation of follitropin binding inhibitor and lutropin binding stimulator. J Biol Chem 1982 Jun 10; 257(11): 6033–40

    PubMed  CAS  Google Scholar 

  5. Wheatcroft NJ, Rogers CA, Metcalfe RA, et al. Is subclinical ovarian failure an autoimmune disease? Hum Reprod 1997 Feb; 12(2): 244–9

    Article  PubMed  CAS  Google Scholar 

  6. Pellicer A, Ballester MJ, Serrano MD, et al. Aetiological factors involved in the low response to gonadotrophins in infertile women with normal basal serum follicle stimulating hormone levels. Hum Reprod 1994 May; 9(5): 806–11

    PubMed  CAS  Google Scholar 

  7. Zeleznik AJ, Schuler HM, Reichert Jr LE. Gonadotropin-binding sites in the rhesus monkey ovary: role of the vasculature in the selective distribution of human chorionic gonadotropin to the preovulatory follicle. Endocrinology 1981 Aug; 109(2): 356–62

    Article  PubMed  CAS  Google Scholar 

  8. Friedman CI, Danforth DR, Herbosa-Encarnacion C, et al. Follicular fluid vascular endothelial growth factor concentrations are elevated in women of advanced reproductive age undergoing ovulation induction. Fertil Steril 1997 Oct; 68(4): 607–12

    Article  PubMed  CAS  Google Scholar 

  9. Gaulden ME. Maternal age effect: the enigma of Down syndrome and other trisomic conditions. Mutat Res 1992 Dec; 296(1–2): 69–88

    PubMed  CAS  Google Scholar 

  10. Perez Mayorga M, Gromoll J, Behre HM, et al. Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. J Clin Endocrinol Metab 2000 Sep; 85(9): 3365–9

    Article  Google Scholar 

  11. Garcia JE, Jones GS, Acosta AA, et al. Human menopausal gonadotropin/human chorionic gonadotropin follicular maturation for oocyte aspiration: phase II, 1981. Fertil Steril 1983 Feb; 39(2): 174–9

    PubMed  CAS  Google Scholar 

  12. Surrey ES, Schoolcraft WB. Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. Fertil Steril 2000 Apr; 73(4): 667–76

    Article  PubMed  CAS  Google Scholar 

  13. Raga F, Bonilla-Musoles F, Casan EM, et al. Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradiol: improved reproductive outcome. Hum Reprod 1999 Jun; 14(6): 1431–4

    Article  PubMed  CAS  Google Scholar 

  14. Busacca M, Fusi FM, Brigante C, et al. Use of growth hormone-releasing factor in ovulation induction in poor responders. J Reprod Med 1996 Sep; 41(9): 699–703

    PubMed  CAS  Google Scholar 

  15. Feldberg D, Farhi J, Ashkenazi J, et al. Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels. Fertil Steril 1994 Aug; 62(2): 343–6

    PubMed  CAS  Google Scholar 

  16. Fridstrom M, Akerlof E, Sjoblom P, et al. Serum levels of luteinizing and follicle-stimulating hormones in normal and poor-responding patients undergoing ovarian stimulation with urofollitropin after pituitary downregulation. Gynecol Endocrinol 1997 Feb; 11(1): 25–8

    Article  PubMed  CAS  Google Scholar 

  17. Serafini P, Stone B, Kerin J, et al. An alternate approach to controlled ovarian hyperstimulation in “poor responders’: pretreatment with a gonadotropin-releasing hormone analog. Fertil Steril 1988 Jan; 49(1): 90–5

    PubMed  CAS  Google Scholar 

  18. Surrey ES, Bower J, Hill DM, et al. Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization. Fertil Steril 1998 Mar; 69(3): 419–24

    Article  PubMed  CAS  Google Scholar 

  19. Lindheim SR, Barad DH, Witt B, et al. Short-term gonadotropin suppression with oral contraceptives benefits poor responders prior to controlled ovarian hyperstimulation. J Assist Reprod Genet 1996 Oct; 13(9): 745–7

    Article  PubMed  CAS  Google Scholar 

  20. Land JA, Yarmolinskaya MI, Dumoulin JC, et al. High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome. Fertil Steril 1996 May; 65(5): 961–5

    PubMed  CAS  Google Scholar 

  21. Lashen H, Ledger W, Lopez-Bernal A, et al. Poor responders to ovulation induction: is proceeding to in-vitro fertilization worthwhile? Hum Reprod 1999 Apr; 14(4): 964–9

    Article  PubMed  CAS  Google Scholar 

  22. Schoolcraft W, Schlenker T, Gee M, et al. Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol. Fertil Steril 1997 Jan; 67(1): 93–7

    Article  PubMed  CAS  Google Scholar 

  23. Karande V, Morris R, Rinehart J, et al. Limited success using the “flare” protocol in poor responders in cycles with low basal follicle-stimulating hormone levels during in vitro fertilization. Fertil Steril 1997 May; 67(5): 900–3

    Article  PubMed  CAS  Google Scholar 

  24. Faber BM, Mayer J, Cox B, et al. Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders. Fertil Steril 1998 May; 69(5): 826–30

    Article  PubMed  CAS  Google Scholar 

  25. Toth TL, Awwad JT, Veeck LL, et al. Suppression and flare regimens of gonadotropin-releasing hormone agonist: use in women with different basal gonadotropin values in an in vitro fertilization program. J Reprod Med 1996 May; 41(5): 321–6

    PubMed  CAS  Google Scholar 

  26. Brzyski RG, Muasher SJ, Droesch K, et al. Follicular atresia associated with concurrent initiation of gonadotropin-releasing hormone agonist and follicle-stimulating hormone for oocyte recruitment. Fertil Steril 1988 Dec; 50(6): 917–21

    PubMed  CAS  Google Scholar 

  27. Karande VC, Jones GS, Veeck LL, et al. High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patients. Fertil Steril 1990 Mar; 53(3): 486–9

    PubMed  CAS  Google Scholar 

  28. Olivennes F, Righini C, Fanchin R, et al. A protocol using a low dose of gonadotrophin-releasing hormone agonist might be the best protocol for patients with high follicle-stimulating hormone concentrations on day 3. Hum Reprod 1996 Jun; 11(6): 1169–72

    Article  PubMed  CAS  Google Scholar 

  29. Droesch K, Muasher SJ, Brzyski RG, et al. Value of suppression with a gonadotropin-releasing hormone agonist prior to gonadotropin stimulation for in vitro fertilization. Fertil Steril 1989 Feb; 51(2): 292–7

    PubMed  CAS  Google Scholar 

  30. Salat-Baroux J, Rotten D, Alvarez S, et al. Comparison of growth hormone responses to growth hormone-releasing factor and clonidine in women with normal or poor ovarian response to gonadotropin stimulation. Fertil Steril 1993 Nov; 60(5): 791–9

    PubMed  CAS  Google Scholar 

  31. Hugues JN, Torresani T, Herve F, et al. Interest of growth hormone-releasing hormone administration for improvement of ovarian responsiveness to gonadotropins in poor responder women. Fertil Steril 1991 May; 55(5): 945–51

    PubMed  CAS  Google Scholar 

  32. Scott RT, Navot D. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. Fertil Steril 1994 May; 61(5): 880–5

    PubMed  CAS  Google Scholar 

  33. Ibrahim ZH, Matson PL, Buck P, et al. The use of biosynthetic human growth hormone to augment ovulation induction with buserelin acetate/human menopausal gonadotropin in women with a poor ovarian response. Fertil Steril 1991 Jan; 55(1): 202–4

    PubMed  CAS  Google Scholar 

  34. Hughes SM, Huang ZH, Morris ID, et al. A double-blind cross-over controlled study to evaluate the effect of human biosynthetic growth hormone on ovarian stimulation in previous poor responders to in-vitro fertilization. Hum Reprod 1994 Jan; 9(1): 13–8

    PubMed  CAS  Google Scholar 

  35. Hofmann GE, Toner JP, Muasher SJ, et al. High-dose follicle-stimulating hormone (FSH) ovarian stimulation in low-responder patients for in vitro fertilization. J In Vitro Fert Embryo Transf 1989 Oct; 6(5): 285–9

    Article  PubMed  CAS  Google Scholar 

  36. Rombauts L, Suikkari AM, MacLachlan V, et al. Recruitment of follicles by recombinant human follicle-stimulating hormone commencing in the luteal phase of the ovarian cycle. Fertil Steril 1998 Apr; 69(4): 665–9

    Article  PubMed  CAS  Google Scholar 

  37. Manzi DL, Thornton KL, Scott LB, et al. The value of increasing the dose of human menopausal gonadotropins in women who initially demonstrate a poor response. Fertil Steril 1994 Aug; 62(2): 251–6

    PubMed  CAS  Google Scholar 

  38. Shaker AG, Fleming R, Jamieson ME, et al. Absence of effect of adjuvant growth hormone therapy on follicular responses to exogenous gonadotropins in women: normal and poor responders. Fertil Steril 1992 Nov; 58(5): 919–23

    PubMed  CAS  Google Scholar 

  39. Chong AP, Rafael RW, Forte CC. Influence of weight in the induction of ovulation with human menopausal gonadotropin and human chorionic gonadotropin. Fertil Steril 1986 Oct; 46(4): 599–603

    PubMed  CAS  Google Scholar 

  40. Katayama KP, Roesler M, Gunnarson C, et al. Short-term use of gonadotropin-releasing hormone agonist (leuprolide) for in vitro fertilization. J In Vitro Fert Embryo Transf1988 Dec; 5(6): 332–4

    Article  PubMed  CAS  Google Scholar 

  41. Padilla SL, Smith RD, Garcia JE. The Lupron screening test: tailoring the use of leuprolide acetate in ovarian stimulation for in vitro fertilization. Fertil Steril 1991 Jul; 56(1): 79–83

    PubMed  CAS  Google Scholar 

  42. de Ziegler D, Cedars MI, Randle D, et al. Suppression of the ovary using a gonadotropin releasing-hormone agonist prior to stimulation for oocyte retrieval. Fertil Steril 1987 Nov; 48(5): 807–10

    PubMed  Google Scholar 

  43. McKenna KM, Foster P, McBain J, et al. Combined treatment with gonadotrophin releasing hormone agonist and gonadotrophins in poor responders to hyperstimulation for in vitro fertilization (IVF): clinical and endocrine results. Aust N Z J Obstet Gynaecol 1989 Nov; 29(4): 428–32

    Article  PubMed  CAS  Google Scholar 

  44. El-Toukhy T, Khalaf Y, Hart R, et al. Young age does not protect against the adverse effects of reduced ovarian reserve: an eight year study. Hum Reprod 2002 Jun; 17(6): 1519–24

    Article  PubMed  Google Scholar 

  45. Sharara FI, Scott Jr RT, Seifer DB. The detection of diminished ovarian reserve in infertile women. Am J Obstet Gynecol 1998 Sep; 179(3 Pt 1): 804–12

    Article  PubMed  CAS  Google Scholar 

  46. Scott Jr RT, Hofmann GE. Prognostic assessment of ovarian reserve. Fertil Steril 1995 Jan; 63(1): 1–11

    PubMed  Google Scholar 

  47. Khalaf Y, El-Toukhy T, Taylor A, et al. Increasing the gonadotrophin dose in the course of an in vitro fertilization cycle does not rectify an initial poor response. Eur J Obstet Gynecol Reprod Biol 2002 Jul 10; 103(2): 146–9

    Article  PubMed  CAS  Google Scholar 

  48. van Hooff MH, Alberda AT, Huisman GJ, et al. Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders: a randomized study. Hum Reprod 1993 Mar; 8(3): 369–73

    PubMed  Google Scholar 

  49. Howies CM, Macnamee MC, Edwards RG. Short term use of an LHRH agonist to treat poor responders entering an in-vitro fertilization programme. Hum Reprod 1987 Nov; 2(8): 655–6

    Google Scholar 

  50. Belaisch-Allart J, Testart J, Frydman R. Utilization of GnRH agonists for poor responders in an IVF programme. Hum Reprod 1989 Jan; 4(1): 33–4

    PubMed  CAS  Google Scholar 

  51. Dor J, Seidman DS, Amudai E, et al. Adjuvant growth hormone therapy in poor responders to in-vitro fertilization: a prospective randomized placebo-controlled double-blind study. Hum Reprod 1995 Jan; 10(1): 40–3

    Article  PubMed  CAS  Google Scholar 

  52. Kim CH, Chae HD, Chang YS. Pyridostigmine cotreatment for controlled ovarian hyperstimulation in low responders undergoing in vitro fertilization-embryo transfer. Fertil Steril 1999 Apr; 71(4): 652–7

    Article  PubMed  CAS  Google Scholar 

  53. Battaglia C, Salvatori M, Maxia N, et al. Adjuvant L-arginine treatment for in-vitro fertilization in poor responder patients. Hum Reprod 1999 Jul; 14(7): 1690–7

    Article  PubMed  CAS  Google Scholar 

  54. Mitwally MF, Casper RF. Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders (1). Fertil Steril 2002 Apr; 77(4): 776–80

    Article  PubMed  Google Scholar 

  55. Craft I, Gorgy A, Hill J, et al. Will GnRH antagonists provide new hope for patients considered ‘difficult responders’ to GnRH agonist protocols? Hum Reprod 1999 Dec; 14(12): 2959–62

    Article  PubMed  CAS  Google Scholar 

  56. Akman MA, Erden HF, Tosun SB, et al. Addition of GnRH antagonist in cycles of poor responders undergoing IVF. Hum Reprod 2000 Oct; 15(10): 2145–7

    Article  PubMed  CAS  Google Scholar 

  57. Akman MA, Erden HF, Tosun SB, et al. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum Reprod 2001 May; 16(5): 868–70

    Article  PubMed  CAS  Google Scholar 

  58. Nikolettos N, Al-Hasani S, Felberbaum R, et al. Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders. Eur J Obstet Gynecol Reprod Biol 2001 Aug; 97(2): 202–7

    Article  PubMed  CAS  Google Scholar 

  59. Bassil S, Godin PA, Donnez J. Outcome of in-vitro fertilization through natural cycles in poor responders. Hum Reprod 1999 May; 14(5): 1262–5

    Article  PubMed  CAS  Google Scholar 

  60. Feldman B, Seidman DS, Levron J, et al. In vitro fertilization following natural cycles in poor responders. Gynecol Endocrinol 2001 Oct; 15(5): 328–34

    PubMed  CAS  Google Scholar 

  61. Garcia JE, Padilla SL, Bayati J, et al. Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization. Fertil Steril 1990 Feb; 53(2): 302–5

    PubMed  CAS  Google Scholar 

  62. Padilla SL, Dugan K, Maruschak V, et al. Use of the flare-up protocol with high dose human follicle stimulating hormone and human menopausal gonadotropins for in vitro fertilization in poor responders. Fertil Steril 1996 Apr; 65(4): 796–9

    PubMed  CAS  Google Scholar 

  63. Cramer DW, Powers DR, Oskowitz SP, et al. Gonadotropin-releasing hormone agonist use in assisted reproduction cycles: the influence of long and short regimens on pregnancy rates. Fertil Steril 1999 Jul; 72(1): 83–9

    Article  PubMed  CAS  Google Scholar 

  64. Kondaveeti-Gordon U, Harrison RF, Barry-Kinsella C, et al. A randomized prospective study of early follicular or midluteal initiation of long protocol gonadotropin-releasing hormone in an in vitro fertilization program. Fertil Steril 1996 Oct; 66(4): 582–6

    PubMed  CAS  Google Scholar 

  65. Loumaye E, Vankrieken L, Depreester S, et al. Hormonal changes induced by short-term administration of gonadotropin-releasing hormone agonist during ovarian hyperstimulation for in vitro fertilization and their consequences for embryo development. Fertil Steril 1989 Jan; 51(1): 105–11

    PubMed  CAS  Google Scholar 

  66. Ron-El R, Herman A, Golan A, et al. The comparison of early follicular and midluteal administration of long-acting gonadotropin-releasing hormone agonist. Fertil Steril 1990 Aug; 54(2): 233–7

    PubMed  CAS  Google Scholar 

  67. Gindoff PR, Hall JL, Stillman RJ. Ovarian suppression with leuprolide acetate: comparison of luteal, follicular, and flare-up administration in controlled ovarian hyperstimulation for oocyte retrieval. J In Vitro Fert Embryo Transf 1990 Apr; 7(2): 94–7

    Article  PubMed  CAS  Google Scholar 

  68. Anserini P, Magnasco A, Remorgida V, et al. Comparison of a blocking vs a flare-up protocol in poor responders with a normal and abnormal clomiphene citrate challenge test. Gynecol Endocrinol 1997 Oct; 11(5): 321–6

    Article  PubMed  CAS  Google Scholar 

  69. De Placido G, Alviggi C, Mollo A, et al. Recombinant follicle stimulating hormone is effective in poor responders to highly purified follicle stimulating hormone. Hum Reprod 2000 Jan; 15(1): 321–6

    Google Scholar 

  70. Dirnfeld M, Fruchter O, Yshai D, et al. Cessation of gonadotropin-releasing hormone analogue (GnRH-a) upon down-regulation versus conventional long GnRH-a protocol in poor responders undergoing in vitro fertilization. Fertil Steril 1999 Sep; 72(3): 406–11

    Article  PubMed  CAS  Google Scholar 

  71. Garcia-Velasco JA, Isaza V, Requena A, et al. High doses of gonadotrophins combined with stop versus non-stop protocol of GnRH analogue administration in low responder IVF patients: a prospective, randomized, controlled trial. Hum Reprod 2000 Nov; 15(11): 2292–6

    Article  PubMed  CAS  Google Scholar 

  72. Sharara FI, McClamrock HD. Use of microdose GnRH agonist protocol in women with low ovarian volumes undergoing IVF. Hum Reprod 2001 Mar; 16(3): 500–3

    Article  PubMed  CAS  Google Scholar 

  73. Leondires MP, Escalpes M, Segars JH, et al. Microdose follicular phase gonadotropin-releasing hormone agonist (GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization. Fertil Steril 1999 Dec; 72(6): 1018–23

    Article  PubMed  CAS  Google Scholar 

  74. Cedrin-Durnerin I, Bstandig B, Herve F, et al. A comparative study of high fixed-dose and decremental-dose regimens of gonadotropins in a minidose gonadotropin-releasing hormone agonist flare protocol for poor responders. Fertil Steril 2000 May; 73(5): 1055–6

    Article  PubMed  CAS  Google Scholar 

  75. Suikkari A, MacLachlan V, Koistinen R, et al. Double-blind placebo controlled study: human biosynthetic growth hormone for assisted reproductive technology. Fertil Steril 1996 Apr; 65(4): 800–5

    PubMed  CAS  Google Scholar 

  76. Levy T, Limor R, Villa Y, et al. Another look at co-treatment with growth hormone and human menopausal gonadotrophins in poor ovarian responders. Hum Reprod 1993 Jun; 8(6): 834–9

    PubMed  CAS  Google Scholar 

  77. Anteby EY, Hurwitz A, Korach O, et al. Human follicular nitric oxide pathway: relationship to follicular size, oestradiol concentrations and ovarian blood flow. Hum Reprod 1996 Sep; 11(9): 1947–51

    Article  PubMed  CAS  Google Scholar 

  78. Tao M, Kodama H, Kagabu S, et al. Possible contribution of follicular interleukin-1beta to nitric oxide generation in human pre-ovulatory follicles. Hum Reprod 1997 Oct; 12(10): 2220–5

    Article  PubMed  CAS  Google Scholar 

  79. Lindheim SR, Vidali A, Ditkoff E, et al. Poor responders to ovarian hyperstimulation may benefit from an attempt at natural-cycle oocyte retrieval. J Assist Reprod Genet 1997 Mar; 14(3): 174–6

    Article  PubMed  CAS  Google Scholar 

  80. Requena A, Neuspiller F, Cobo AC, et al. The potential use of maturation in vitro of human oocytes in low responder patients. J Assist Reprod Genet 2000 May; 17(5): 239–44

    Article  PubMed  CAS  Google Scholar 

  81. Hernandez ER, Hurwitz A, Vera A, et al. Expression of the genes encoding the insulin-like growth factors and their receptors in the human ovary. J Clin Endocrinol Metab 1992 Feb; 74(2): 419–25

    Article  PubMed  CAS  Google Scholar 

  82. Scott RT, Toner JP, Muasher SJ, et al. Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril 1989 Apr; 51(4): 651–4

    PubMed  CAS  Google Scholar 

  83. Bukman A, Heineman MJ. Ovarian reserve testing and the use of prognostic models in patients with subfertility. Hum Reprod Update 2001 Nov–Dec; 7(6): 581–90

    Article  PubMed  CAS  Google Scholar 

  84. Wallach EE. Pitfalls in evaluating ovarian reserve. Fertil Steril 1995 Jan; 63(1): 12–4

    PubMed  CAS  Google Scholar 

  85. Gulekli B, Bulbul Y, Onvural A, et al. Accuracy of ovarian reserve tests. Hum Reprod 1999 Nov; 14(11): 2822–6

    Article  PubMed  CAS  Google Scholar 

  86. Esposito MA, Coutifaris C, Barnhart KT. A moderately elevated day 3 FSH concentration has limited predictive value, especially in younger women. Hum Reprod 2002 Jan; 17(1): 118–23

    Article  PubMed  CAS  Google Scholar 

  87. Ludwig M, Strik D, Al-Hasani S, et al. No transfer in a planned ICSI cycle: we cannot overcome some basic rules of human reproduction. Eur J Obstet Gynecol Reprod Biol 1999 Nov; 87(1): 3–11

    Article  PubMed  CAS  Google Scholar 

  88. Levi AJ, Segars JH, Miller BT, et al. Endometrial cavity fluid is associated with poor ovarian response and increased cancellation rates in ART cycles. Hum Reprod 2001 Dec; 16(12): 2610–5

    Article  PubMed  CAS  Google Scholar 

  89. Phophong P, Ranieri DM, Khadum I, et al. Basal 17beta-estradiol did not correlate with ovarian response and in vitro fertilization treatment outcome. Fertil Steril 2000 Dec; 74(6): 1133–6

    Article  PubMed  CAS  Google Scholar 

  90. Noci I, Biagiotti R, Maggi M, et al. Low day 3 luteinizing hormone values are predictive of reduced response to ovarian stimulation. Hum Reprod 1998 Mar; 13(3): 531–4

    Article  PubMed  CAS  Google Scholar 

  91. Sharara FI, McClamrock HD. Ratio of oestradiol concentration on the day of human chorionic gonadotrophin administration to mid-luteal oestradiol concentration is predictive of in-vitro fertilization outcome. Hum Reprod 1999 Nov; 14(11): 2777–82

    Article  PubMed  CAS  Google Scholar 

  92. Scheffer GJ, Broekmans FJ, Dorland M, et al. Antral follicle counts by transvaginal ultrasonography are related to age in women with proven natural fertility. Fertil Steril 1999 Nov; 72(5): 845–51

    Article  PubMed  CAS  Google Scholar 

  93. Chang MY, Chiang CH, Hsieh TT, et al. Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertil Steril 1998 Mar; 69(3): 505–10

    Article  PubMed  CAS  Google Scholar 

  94. Pellicer A, Ardiles G, Neuspiller F, et al. Evaluation of the ovarian reserve in young low responders with normal basal levels of follicle-stimulating hormone using three-dimensional ultrasonography. Fertil Steril 1998 Oct; 70(4): 671–5

    Article  PubMed  CAS  Google Scholar 

  95. Frattarelli JL, Lauria-Costab DF, Miller BT, et al. Basal antral follicle number and mean ovarian diameter predict cycle cancellation and ovarian responsiveness in assisted reproductive technology cycles. Fertil Steril 2000 Sep; 74(3): 512–7

    Article  PubMed  CAS  Google Scholar 

  96. Bancsi LF, Broekmans FJ, Eijkemans MJ, et al. Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertil Steril 2002 Feb; 77(2): 328–36

    Article  PubMed  Google Scholar 

  97. Pohl M, Hohlagschwandtner M, Obruca A, et al. Number and size of antral follicles as predictive factors in vitro fertilization and embryo transfer. J Assist Reprod Genet 2000 Jul; 17(6): 315–8

    Article  PubMed  CAS  Google Scholar 

  98. Syrop CH, Willhoite A, Van Voorhis BJ. Ovarian volume: a novel outcome predictor for assisted reproduction. Fertil Steril 1995 Dec; 64(6): 1167–71

    PubMed  CAS  Google Scholar 

  99. Kyei-Mensah A, Zaidi J, Pittrof R, et al. Transvaginal three-dimensional ultrasound: accuracy of follicular volume measurements. Fertil Steril 1996 Feb; 65(2): 371–6

    PubMed  CAS  Google Scholar 

  100. Kyei-Mensah A, Maconochie N, Zaidi J, et al. Transvaginal three-dimensional ultrasound: reproducibility of ovarian and endometrial volume measurements. Fertil Steril 1996 Nov; 66(5): 718–22

    PubMed  CAS  Google Scholar 

  101. Engmann L, Sladkevicius P, Agrawal R, et al. Value of ovarian stromal blood flow velocity measurement after pituitary suppression in the prediction of ovarian responsiveness and outcome of in vitro fertilization treatment. Fertil Steril 1999 Jan; 71(1): 22–9

    Article  PubMed  CAS  Google Scholar 

  102. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997 Feb; 18(1): 4–25

    Article  PubMed  CAS  Google Scholar 

  103. Battaglia C, Genazzani AD, Regnani G, et al. Perifollicular Doppler flow and follicular fluid vascular endothelial growth factor concentrations in poor responders. Fertil Steril 2000 Oct; 74(4): 809–12

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. IVF Program, Karande and Associates, 1585 North Barrington Road, Suite 406, Hoffman Estates, Illinois, 60194, USA

    Vishvanath C. Karande

Authors
  1. Vishvanath C. Karande
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vishvanath C. Karande.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karande, V.C. Managing and Predicting Low Response to Standard In Vitro Fertilization Therapy. Mol Diag Ther 2, 257–272 (2003). https://doi.org/10.2165/00024677-200302040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024677-200302040-00004

Keywords

Search

Navigation